Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort
Fabry disease (FD) is a multisystem lysosomal storage disorder induced by genetic variants in the alpha-galactosidase A (αGalA) gene. Some FD patients have GLA variants with a reduction in overall αGalA enzymatic activity due to mutated proteins with reduced stability, caused by protein misfolding a...
Saved in:
| Main Authors: | Sebastián Jaurretche, Santiago Alonso, Mónica Calvo, Sebastián Fernandez, Heber Figueredo, Beatriz Galli, Ivanna Marin, Andrés Martinez, Silvia Mattausch, Fernando Perretta, Juan Politei, Juan Ignacio Rolon, Esteban Calabrese |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Global Health, Epidemiology and Genomics |
| Online Access: | http://dx.doi.org/10.1155/2024/9293896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WCN24-2159 REAL-WORLD EVIDENCE REGARDING RENAL EFFECT OF MIGALASTAT
by: Sebastián Jaurretche, et al.
Published: (2024-04-01) -
Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report
by: Natalja Haninger-Vacariu, et al.
Published: (2019-01-01) -
Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease
by: Malte Lenders, et al.
Published: (2025-02-01) -
Fabry Disease: An Update Based on Evidence and Experience
by: J. Politei, et al.
Published: (2025-06-01) -
Fabry nephropathy. Urinary expression of podocyte proteins mRNA and microRNAs in non-albuminuric patients
by: Sebastián Jaurretche, et al.
Published: (2024-07-01)